Arca
Skip to content
Tools
Tools

Cytochrome P450 3A

Family in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 2
  • In phases 1 to 3: 0
  • Sponsors: 2
  • Genes: 4

Who is on it, and how far along

Every drug ChEMBL records acting on CYP3A4, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved2

  • Ritonavir
  • Cobicistat

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        RitonavirBoxed warningApprovedAbbVieSmall moleculeInhibitorCytochrome P450 3A inhibitor37
        CobicistatApprovedGilead SciencesSmall moleculeInhibitorCytochrome P450 3A inhibitor13

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 15 in all, from ClinicalTrials.gov.
        An Evaluation of the Potential for VH4011499 Drug-drug-interactionsRitonavirPhase 1Not yet recruitingViiV HealthcareNov 16, 2026
        An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaRitonavirPhase 3Not yet recruitingUniversity College, LondonAug 28, 2026
        Treatment of CKD Patients With HCVRitonavirPhase 2 / Phase 3Not yet recruitingTanta UniversityAug 18, 2026
        Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upCobicistatPhase 4RecruitingInstituto Mexicano del Seguro SocialJul 1, 2026
        A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)RitonavirPhase 2RecruitingDaré Bioscience, Inc.May 22, 2026
        SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID DysfunctionRitonavirPhase 2RecruitingIcahn School of Medicine at Mount SinaiMay 19, 2026
        KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction StudyCobicistatPhase 1Not yet recruitingHelsinki University Central HospitalMar 10, 2026
        OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 PatientsRitonavirPhase 2RecruitingCalmy AlexandraFeb 12, 2026
        Research on the Psychological Status of Patients With HIV-1 InfectionCobicistat, Ritonavir—Not yet recruitingShanxi Bethune HospitalJul 23, 2025
        Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in MexicoCobicistatPhase 4RecruitingJosé Antonio Mata MarínApr 2, 2025
        Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIVRitonavirPhase 2Active, not recruitingFederal University of São PauloJan 29, 2025
        Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1CobicistatPhase 3Active, not recruitingGilead SciencesOct 8, 2024
        Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV VirusesCobicistatPhase 2Not yet recruitingANRS, Emerging Infectious DiseasesApr 1, 2024
        A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsCobicistatPhase 4RecruitingGilead SciencesMar 29, 2024
        B-free Multistage TrialCobicistatPhase 4Enrolling by invitationInsel Gruppe AG, University Hospital BernSep 14, 2023

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364675, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.